Citi Appointed as Depositary Bank for Innate Pharma’s ADR Programme
Innate Pharma’s American Depositary Shares (“ADS”) trade on the Nasdaq Global Select Market under the symbol “IPHA”. Each ADS represents one ordinary share of the company. Innate Pharma’s underlying ordinary shares are listed and trade on Euronext Paris under the symbol “IPH”.'
Commenting on the appointment,
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from
Innate has been a pioneer in the understanding of NK cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S,
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.
Additional information may be found at www.
Citi Media Contacts:
+44 (0) 20 7508 3082